Global Bacteriophages Therapy Market
Размер рынка в млрд долларов США
CAGR :
% 
 Прогнозируемый период |
2022 –2029 |
 Размер рынка (базовый год) |
USD 39.80 Million |
 Размер рынка (прогнозируемый год) |
USD 64.40 Million |
 CAGR |
% |
| Основные игроки рынка |
Глобальный рынок терапии бактериофагами по целевым показателям (Escherichia Coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella и другие), типу (литический, лизогенный), основе (стерильная бульонная культура, водорастворимая желейная основа), применению (бактериальная дизентерия, инфекции кожи и слизистой оболочки носа, гнойные инфекции кожи, инфекции легких и плевры, инфекции послеоперационных ран и другие), способу введения (перорально, парентерально, ректально, дермально и другие), конечным пользователям (больницы, специализированные клиники, уход на дому и другие), каналу сбыта (больничная аптека, розничная аптека, интернет-аптека и другие) — тенденции отрасли и прогноз до 2029 г.
Анализ и размер рынка
Устойчивость к антибиотикам становится все более распространенной во всем мире, что повышает спрос на эффективные альтернативы. По данным CDC, ежегодно в Европе от устойчивых к антибиотикам бактериальных инфекций страдают около 33 000 человек. Прогнозируется, что устойчивость к антибиотикам будет расти во всем мире, создавая значительный спрос на бактериофаги. Фаготерапия — это еще одно название терапии бактериофагами. Для лечения бактериальных инфекций используются вирусы. Бактериофаги — это бактериальные вирусы. Фаги — это вирусы, убивающие бактерии, которые безвредны для растений, животных и людей. Бактериофаги считаются естественными противниками бактерий. Бактериофаги можно найти в сточных водах, воде, почве и других средах, где существуют бактерии.
По данным анализа Data Bridge Market Research, рынок терапии бактериофагами в 2021 году оценивался в 39,80 млн долларов США, а к 2029 году, как ожидается, достигнет 64,40 млн долларов США, что соответствует среднегодовому темпу роста (CAGR) 6,20% в прогнозируемый период с 2022 по 2029 год. Помимо таких данных о рынке, как рыночная стоимость, темпы роста, сегменты рынка, географический охват, участники рынка и рыночный сценарий, отчет о рынке, подготовленный командой Data Bridge Market Research, также включает в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ линейки препаратов, анализ цен и нормативно-правовую базу.
Область отчета и сегментация рынка
|
Отчет Метрика |
Подробности |
|
Прогнозируемый период |
2022-2029 |
|
Базовый год |
2021 |
|
Исторические годы |
2020 (Можно настроить на 2014 - 2019) |
|
Количественные единицы |
Доход в млн. долл. США, объемы в единицах, цены в долл. США |
|
Охваченные сегменты |
Цель (Escherichia Coli, Staphylococcus, Streptococcus, Pseudomonas, Salmonella и другие), Тип (литический, лизогенный), Основа (стерильная бульонная культура, водорастворимая желейная основа), Применение (бактериальная дизентерия, инфекции кожи и слизистой оболочки носа, гнойные инфекции кожи, легочные и плевральные инфекции, послеоперационные раневые инфекции и другие), Способ введения (пероральный, парентеральный, ректальный, кожный и другие), Конечные пользователи (больницы, специализированные клиники, уход на дому и другие), Канал распространения (больничная аптека, розничная аптека, интернет-аптека и другие) |
|
Страны, охваченные |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Microgen (U.S.), Micreos (Netherlands), ATCC (U.S.), Intralytix, Inc. (U.S.), Adaptive Phage Therapeutics (U.S.), Armata pharmaceuticals Inc. (U.S.),LOCUS BIOSCIENCES, INC. (U.S.), Delmont Laboratories, Inc. (U.S.), Nextbiotics (U.S.), Pherecydes Pharma (France), iNtODEWORLD. Inc. (U.S.), Enbiotix (U.S.), Fixed-Phage Limited (U.K.), Cytophage Technologies Inc. (Canada), Eliava Bio Preparations LTD (Georgia), Phagelux, Inc. (China), InnoPhage, Ltd (Hong Kong), TechnoPhage (Portugal), Eligo Bioscience SA (France), BiomX Ltd. (Israel) |
|
Market Opportunities |
|
Market Definition
Bacteriophages, are viruses that kill and target bacteria exclusively. They're one of the most frequent biological entities capable of fighting and killing multidrug-resistant bacteria. When all other antibiotics have failed to treat an infection, phages can eliminate the bacteria causing the infection, allowing medical experts to save a life. Bacteriophages are being considered an antibiotic replacement. Viruses are employed in this therapy to inject their genetic material into bacteria and grow using their host machinery. This phage therapy is utilized in the body of patients to cure or prevent bacterial diseases. Bacteriophage therapy is also important in the disciplines of molecular biology and technological research. These characteristics broaden the possibility for medication development. Bacteriophages are also termed as Phages.
Bacteriophages Therapy Market Dynamics
Drivers
- High prevalence rate of foodborne diseases
The rise in prevalence rate of foodborne diseases across the globe will act as a major driver that will result in the expansion of the market's growth rate. Foodborne infections caused by spoiled food are becoming more common. Pathogenic bacteria and viruses are present in spoiled food. According to the WHO, about 600 million people (almost one out of every ten people on the planet) will become ill and 420,000 will die as a result of contaminated food in 2019, resulting in the loss of 33 million healthy life years (DALYs). Furthermore, children under the age of five years bear 40% of the burden of foodborne disease, with 125,000 deaths every year. This aspect is propelling the bacteriophages therapy market forward.
- Increasing investment for healthcare infrastructure
Другим существенным фактором, влияющим на темпы роста рынка бактериофаговой терапии, является рост расходов на здравоохранение, что помогает в улучшении его инфраструктуры. Кроме того, различные государственные организации стремятся улучшить инфраструктуру здравоохранения путем увеличения финансирования, и это еще больше повлияет на динамику рынка.
- Растущая распространенность инфекций, устойчивых к антибиотикам
Ожидается, что растущая распространенность инфекций, устойчивых к антибиотикам, будет способствовать росту рынка. Растущая распространенность инфекций, устойчивых к антибиотикам, привела к увеличению расходов здравоохранения на их лечение и увеличению числа смертей. По данным Центров по контролю и профилактике заболеваний (CDC), в 2019 году в США около 2 миллионов человек заразятся инфекциями, устойчивыми к антибиотикам, и ежегодно умирают не менее 23 000 человек. По данным Всемирной организации здравоохранения, в 2016 году более 490 000 человек во всем мире были инфицированы туберкулезом с множественной лекарственной устойчивостью. Эта лекарственная устойчивость усложняет лечение людей, страдающих от других заболеваний, включая малярию и ВИЧ.
Кроме того, растущее число правительственных инициатив по распространению информации и увеличение гериатрического населения приведут к расширению рынка бактериофаговой терапии. Наряду с этим, изменение образа жизни людей и повышение уровня располагаемого дохода увеличат темпы роста рынка.
Возможности
- Увеличение количества научно-исследовательских и опытно-конструкторских работ
Более того, рост рынка подпитывается увеличением числа научно-исследовательских и опытно-конструкторских работ. Это предоставит благоприятные возможности для роста рынка терапии бактериофагами. Например, в январе 2019 года Управление по контролю за продуктами и лекарствами США одобрило запрос от врачей-ученых Медицинской школы Калифорнийского университета в Сан-Диего на проведение первого в США клинического испытания терапии на основе бактериофагов, вводимых внутривенно. Планируемый эксперимент будет проводиться в партнерстве с AmpliPhi Biosciences Corporation, биотехнологической фирмой из Сан-Диего.
Более того, рост рынка подпитывается инвестициями в разработку передовых технологий и увеличением числа развивающихся рынков. Эти факторы предоставят благоприятные возможности для роста рынка бактериофаговой терапии.
Ограничения/Проблемы
С другой стороны, высокая стоимость, связанная с терапией бактериофагами, будет сдерживать темпы роста рынка терапии бактериофагами в прогнозируемый период 2022-2029 гг. Отсутствие инфраструктуры здравоохранения в развивающихся экономиках и строгий сценарий регулирования будут бросать вызов рынку терапии бактериофагами. Кроме того, неосведомленность людей и отсутствие альтернатив будут сдерживать и еще больше затруднять темпы роста рынка в прогнозируемый период 2022-2029 гг.
В этом отчете о рынке терапии бактериофагами содержатся сведения о последних новых разработках, правилах торговли, анализе импорта-экспорта, анализе производства, оптимизации цепочки создания стоимости, доле рынка, влиянии внутренних и локальных игроков рынка, анализируются возможности с точки зрения новых источников дохода, изменений в правилах рынка, анализ стратегического роста рынка, размер рынка, рост рынка категорий, ниши применения и доминирование, одобрения продуктов, запуски продуктов, географические расширения, технологические инновации на рынке. Чтобы получить больше информации о рынке терапии бактериофагами, свяжитесь с Data Bridge Market Research для получения аналитического обзора, наша команда поможет вам принять обоснованное рыночное решение для достижения роста рынка.
Анализ эпидемиологии пациентов
Рынок терапии бактериофагами также предоставляет вам подробный анализ рынка для анализа пациентов, прогнозов и излечения. Распространенность, заболеваемость, смертность, показатели приверженности — вот некоторые из переменных данных, которые доступны в отчете. Анализируется прямое или косвенное влияние эпидемиологии на рост рынка для создания более надежной и когортной многомерной статистической модели для прогнозирования рынка в период роста.
Влияние COVID-19 на рынок терапии бактериофагами
Заболевание распространилось более чем в 100 странах с момента вспышки вируса COVID-19 в декабре 2019 года, что побудило Всемирную организацию здравоохранения объявить его чрезвычайной ситуацией в области общественного здравоохранения. Кроме того, пандемия COVID-19 создала серьезные проблемы для компаний на мировом рынке бактериофаговой терапии по нескольким направлениям. Поставка сырья для производства лекарственных препаратов была большой проблемой из-за несоответствий в работе транспортных средств. Кроме того, из-за роста числа пациентов, страдающих от COVID-19 и других опасных для жизни состояний, дистрибьюторы товаров столкнулись с нестабильным спросом со стороны розничных торговцев. Пандемия COVID-19 нарушила клинические испытания в Соединенных Штатах, затронув важных игроков во всем секторе. Отпуск персонала, протоколы социального дистанцирования, финансовые потери и опасения по поводу безопасности пациентов — все это повлияло на возможности исследовательских площадок. Спонсоры, CRO и другие компании, поддерживающие разработку лекарств, перешли на удаленную работу. В результате пандемии COVID-19, по оценкам, 80% испытаний, не связанных с COVID-19, были остановлены или прерваны.
Глобальный охват рынка терапии бактериофагами
Рынок бактериофаговой терапии сегментирован на основе цели, типа, базы, применения, пути введения, конечного пользователя и канала сбыта. Рост среди этих сегментов поможет вам проанализировать сегменты с незначительным ростом в отраслях и предоставить пользователям ценный обзор рынка и рыночные идеи, которые помогут им принимать стратегические решения для определения основных рыночных приложений.
Цель
- Escherichia coli (кишечная палочка)
- Стафилококк
- стрептококк
- Псевдомонады
- Сальмонелла
- Другие
Тип
- Литический
- Лизогенный
База
- Стерильная культура бульона
- Водорастворимая желейная основа
Приложение
- Бактериальная дизентерия
- Infections of Skin And Nasal Mucosa
- Suppurative Skin Infection
- Lung and Pleural Infections
- Postoperative Wound Infections
- Others
Route of Administration
- Oral
- Parenteral
- Rectal
- Dermal
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Bacteriophages Therapy Market Regional Analysis/Insights
The bacteriophages therapy market is analysed and market size insights and trends are provided by country, target, type, base, application, route of administration, end-user, and distribution channel as referenced above.
The countries covered in the bacteriophages therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the bacteriophages therapy market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the immediate recovery and therapeutic effect provided by lytic bacteriophage and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, the presence of major key players and rise in adoption of newer technologies will further propel the market's growth rate in this region.
Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to increasing investment in innovative R&D for novel drug products in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Bacteriophages Therapy Market Share Analysis
Конкурентная среда рынка бактериофаговой терапии содержит сведения по конкурентам. Включены сведения о компании, финансах компании, полученном доходе, рыночном потенциале, инвестициях в исследования и разработки, новых рыночных инициативах, глобальном присутствии, производственных площадках и объектах, производственных мощностях, сильных и слабых сторонах компании, запуске продукта, широте и широте продукта, доминировании в применении. Приведенные выше данные касаются только фокуса компаний на рынке бактериофаговой терапии.
Некоторые из основных игроков, работающих на рынке терапии бактериофагами:
- Микроген (США)
- Микроос (Нидерланды)
- ATCC (США)
- Intralytix, Inc. (США)
- Адаптивная фаговая терапия (США)
- Armata Pharmaceuticals Inc. (США)
- LOCUS BIOSCIENCES, INC. (США)
- Delmont Laboratories, Inc. (США)
- Nextbiotics (США)
- Ферецид Фарма (Франция)
- iNtoDEWORLD. Inc. (США)
- Энбиотикс (США)
- Fixed-Phage Limited (Великобритания)
- Cytophage Technologies Inc. (Канада)
- Eliava Bio Preparations LTD (Грузия)
- Phagelux, Inc. (Китай)
- InnoPhage, Ltd (Гонконг)
- TechnoPhage (Португалия)
- Eligo Bioscience SA (Франция)
- BiomX Ltd. (Израиль)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Содержание
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL BACTERIOPHAGES THERAPY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TAREGET LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES MODEL
4.2 PESTEL ANALYSIS
5 GLOBAL BACTERIOPHAGES THERAPY MARKET: REGULATIONS
5.1 THE U.S. REGULATORY GUIDELINES FOR BACTERIOPHAGES
5.2 EUROPE REGULATORY GUIDELINE FOR BACTERIOPHAGE
5.3 JAPAN REGULATORY GUIDELINE FOR BACTERIOPHAGE
5.4 AUSTRALIA REGULATORY GUIDELINE FOR BACTERIOPHAGE
6 GLOBAL BACTERIOPHAGES THERAPY MARKET: REGIONAL SUMMARY
7 RESEARCH AND DEVELOPMENT ANALYSIS: GLOBAL BACTERIOPHAGES THERAPY MARKET
7.1 PIPELINE ANALYSIS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF ANTIBIOTIC-RESISTANT INFECTIONS
8.1.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
8.1.3 INCREASING GOVERNMENT FUNDING
8.1.4 INCREASING PRIVATE SECTOR FUNDING
8.1.5 TECHNOLOGICAL ADVANCEMENTS
8.2 RESTRAINTS
8.2.1 HIGH COST ASSOCIATED WITH BACTERIOPHAGE THERAPY
8.2.2 LACK OF SKILLED PROFESSIONALS
8.2.3 SIDE-EFFECTS OF BACTERIOPHAGE THERAPY
8.2.4 AVAILABILITY OF ALTERNATIVE THERAPIES FOR ANTIBIOTIC RESISTANCE
8.3 OPPORTUNITIES
8.3.1 PRESENCE OF NOVEL PIPELINE DRUGS
8.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
8.3.3 INCREASING HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 LIMITATIONS OF BACTERIOPHAGE THERAPY
8.4.2 LACK OF PROPER REGULATORY GUIDELINES
9 IMPACT OF COVID-19 ON GLOBAL BACTERIOPHAGES THERAPY MARKET
9.1 IMPACT ON THE PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY
9.4 STRATEGIC INITIATIVES BY MANUFACTURERS
9.5 CONCLUSION
10 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY TARGET
10.1 OVERVIEW
10.2 STAPHYLOCOCCUS
10.3 ESCHERICHIA COLI
10.4 PSEUDOMONAS
10.5 STREPTOCOCCUS
10.6 SALMONELLA
10.7 OTHERS
11 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY TYPE
11.1 OVERVIEW
11.2 LYTIC
11.3 LYSOGENIC
12 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY BASE
12.1 OVERVIEW
12.2 STERILE BROTH CULTURE
12.3 WATER-SOLUBLE JELLY BASE
13 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 POSTOPERATIVE WOUND INFECTIONS
13.3 INFECTIONS OF SKIN AND NASAL MUCOSA
13.4 BACTERIAL DYSENTERY
13.5 SUPPURATIVE SKIN INFECTIONS
13.6 LUNG AND PLEURAL INFECTION
13.7 OTHERS
14 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 LIQUID
14.2.2 TABLET
14.3 DERMAL
14.4 PARENTERAL
14.4.1 INTRAVENOUSLY
14.4.2 INTRAPLEURAL INJECTIONS
14.5 OTHERS
15 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECILAITY CLINICS
15.4 ACADEMIC RESEARCH & INSTITUTES
15.5 OTHERS
16 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 THIRD PARTY DISTRIBUTORS
17 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY REGION
17.1 OVERVIEW
17.2 NORTH AMERICA
17.2.1 U.S.
17.2.2 CANADA
17.3 EUROPE
17.3.1 GEORGIA
17.3.2 RUSSIA
17.3.3 BELGIUM
17.3.4 POLAND
17.3.5 FRANCE
17.3.6 NETHERLANDS
17.3.7 U.K.
17.3.8 ITALY
17.3.9 GERMANY
17.3.10 TURKEY
17.3.11 SWITZERLAND
17.3.12 REST OF EUROPE
17.4 MIDDLE EAST & AFRICA
17.4.1 SOUTH AFRICA
17.4.2 SAUDI ARABIA
17.4.3 ISRAEL
17.4.4 EGYPT
17.4.5 REST OF MIDDLE EAST & AFRICA
17.5 ASIA-PACIFIC
17.5.1 CHINA
17.5.2 JAPAN
17.5.3 INDIA
17.5.4 AUSTRALIA
17.5.5 SOUTH KOREA
17.5.6 SINGAPORE
17.5.7 REST OF ASIA-PACIFIC
17.6 SOUTH AMERICA
17.6.1 BRAZIL
17.6.2 ARGENTINA
17.6.3 REST OF SOUTH AMERICA
18 GLOBAL BACTERIOPHAGES THERAPY MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: GLOBAL
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 MICROGEN
20.1.1 COMPANY SNAPSHOT
20.1.2 COMPANY SHARE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENTS
20.2 ADAPTIVE PHAGE THERAPEUTICS
20.2.1 COMPANY SNAPSHOT
20.2.2 COMPANY SHARE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENTS
20.3 PHAGELUX,INC
20.3.1 COMPANY SNAPSHOT
20.3.2 COMPANY SHARE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 LOCUS BIOSCIENCES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 COMPANY SHARE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENTS
20.5 ATCC
20.5.1 COMPANY SNAPSHOT
20.5.2 COMPANY SHARE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENTS
20.6 INTRALYTIX, INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENTS
20.7 MICREOS
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 PYLUM
20.8.1 COMPANY SNAPSHOT
20.8.2 TECHNOLOGY PORTFOLIO
20.8.3 RECENT DEVELOPMENTS
20.9 FIXED-PHAGE LIMITED
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENTS
20.1 ARMATA PHARMACEUTICALS, INC.
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 ARTHUR ANDREW MEDICAL
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 CYTOPHAGE TECHNOLOGIES INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 ENBIOTIX, INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENTS
20.14 INTODEWORLD, INC.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 NEXTBIOTICS
20.15.1 COMPANY SNAPSHOT
20.15.2 TECHNOLOGY PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 PHERECYDES PHARMA
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
Список таблиц
TABLE 1 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 2 GLOBAL STAPHYLOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 GLOBAL ESCHERICHIA COLI IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 GLOBAL PSEUDOMONAS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 GLOBAL STREPTOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 GLOBAL SALMONELLA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 GLOBAL LYTIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 GLOBAL LYSOGENIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 12 GLOBAL STERILE BROTH CULTURE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 GLOBAL WATER-SOLUBLE JELLY BASE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 15 GLOBAL POSTOPERATIVE WOUND INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 GLOBAL INFECTIONS OF SKIN AND NASAL MUCOSA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 GLOBAL BACTERIAL DYSENTERY IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 GLOBAL SUPPURATIVE SKIN INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 GLOBAL LUNG AND PLEURAL INFECTION IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 22 GLOBAL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 GLOBAL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 24 GLOBAL DERMAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 GLOBAL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 GLOBAL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 29 GLOBAL HOSPITALS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 GLOBAL SPECILIATY CLINICS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 GLOBAL ACADEMIC RESEARCH & INSTITUTES IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 34 GLOBAL DIRECT TENDER IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 GLOBAL THIRD PARTY DISTRIBUTORS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 38 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 39 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 40 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 41 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 42 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 43 NORTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 44 NORTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 45 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 46 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 47 U.S. BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 48 U.S. BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 U.S. BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 50 U.S. BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 51 U.S. BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 52 U.S. ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 U.S. PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 54 U.S. BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 55 U.S. BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 56 CANADA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 57 CANADA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 CANADA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 59 CANADA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 60 CANADA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 61 CANADA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 62 CANADA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 63 CANADA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 64 CANADA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 65 EUROPE BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 66 EUROPE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 67 EUROPE BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 EUROPE BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 69 EUROPE BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 70 EUROPE BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 71 EUROPE ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 EUROPE PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 73 EUROPE BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 74 EUROPE BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 75 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 76 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 78 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 79 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 80 GEORGIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 GEORGIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 82 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 83 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 84 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 85 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 86 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 87 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 88 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 89 RUSSIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 90 RUSSIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 91 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 93 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 94 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 96 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 97 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 98 BELGIUM ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 99 BELGIUM PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 100 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 101 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 102 POLAND BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 103 POLAND BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 104 POLAND BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 105 POLAND BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 106 POLAND BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 107 POLAND ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 108 POLAND PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 109 POLAND BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 110 POLAND BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 111 FRANCE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 112 FRANCE BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 FRANCE BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 114 FRANCE BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 115 FRANCE BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 116 FRANCE ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 117 FRANCE PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 118 FRANCE BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 119 FRANCE BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 120 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 121 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 123 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 124 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 125 NETHERLANDS ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 126 NETHERLANDS PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 127 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 128 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 129 U.K. BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 130 U.K. BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 U.K. BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 132 U.K. BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 133 U.K. BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 134 U.K. ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 135 U.K. PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 136 U.K. BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 137 U.K. BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 138 ITALY BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 139 ITALY BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 140 ITALY BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 141 ITALY BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 142 ITALY BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 143 ITALY ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 144 ITALY PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 145 ITALY BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 146 ITALY BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 147 GERMANY BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 148 GERMANY BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 149 GERMANY BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 150 GERMANY BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 151 GERMANY BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 152 GERMANY ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 153 GERMANY PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 154 GERMANY BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 155 GERMANY BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 156 TURKEY BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 157 TURKEY BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 TURKEY BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 159 TURKEY BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 160 TURKEY BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 161 TURKEY ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 162 TURKEY PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 163 TURKEY BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 164 TURKEY BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 165 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 166 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 167 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 168 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 169 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 170 SWITZERLAND ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 171 SWITZERLAND PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 172 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 173 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 174 REST OF EUROPE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 175 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 176 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 177 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 179 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 180 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 181 MIDDLE EAST & AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 182 MIDDLE EAST & AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 183 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 184 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 185 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 186 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 187 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 188 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 189 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 190 SOUTH AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 191 SOUTH AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 192 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 193 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 194 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 195 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 196 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 197 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 198 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 199 SAUDI ARABIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 200 SAUDI ARABIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 201 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 202 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 203 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 204 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 205 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 206 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 207 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 208 ISRAEL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 209 ISRAEL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 210 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 211 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 212 EGYPT BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 213 EGYPT BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 214 EGYPT BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 215 EGYPT BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 216 EGYPT BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 217 EGYPT ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 218 EGYPT PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 219 EGYPT BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 220 EGYPT BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 221 REST OF MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 222 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 223 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 224 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 225 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 226 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 227 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 228 ASIA-PACIFIC ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 229 ASIA-PACIFIC PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 230 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 231 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 232 CHINA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 233 CHINA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 234 CHINA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 235 CHINA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 236 CHINA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 237 CHINA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 238 CHINA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 239 CHINA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 240 CHINA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 241 JAPAN BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 242 JAPAN BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 243 JAPAN BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 244 JAPAN BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 245 JAPAN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 246 JAPAN ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 247 JAPAN PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 248 JAPAN BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 249 JAPAN BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 250 INDIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 251 INDIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 252 INDIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 253 INDIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 254 INDIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 255 INDIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 256 INDIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 257 INDIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 258 INDIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 259 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 260 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 261 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 262 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 263 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 264 AUSTRALIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 265 AUSTRALIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 266 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 267 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 268 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 269 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 270 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 271 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 272 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 273 SOUTH KOREA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 274 SOUTH KOREA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 275 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 276 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 277 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 278 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 279 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 280 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 281 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 282 SINGAPORE ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 283 SINGAPORE PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 284 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 285 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 286 REST OF ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 287 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 288 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 289 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 290 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 291 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 292 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 293 SOUTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 294 SOUTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 295 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 296 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 297 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 298 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 299 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 300 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 301 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 302 BRAZIL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 303 BRAZIL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 304 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 305 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 306 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 307 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 308 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 309 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 310 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 311 ARGENTINA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 312 ARGENTINA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 313 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 314 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 315 REST OF SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
Список рисунков
FIGURE 1 GLOBAL BACTERIOPHAGES THERAPY MARKET: SEGMENTATION
FIGURE 2 GLOBAL BACTERIOPHAGES THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL BACTERIOPHAGES THERAPY MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL BACTERIOPHAGES THERAPY MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL BACTERIOPHAGES THERAPY MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL BACTERIOPHAGES THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL BACTERIOPHAGES THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL BACTERIOPHAGES THERAPY MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 GLOBAL BACTERIOPHAGES THERAPY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL BACTERIOPHAGES THERAPY MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCE OF ANTIBIOTIC-RESISTANT INFECTIONS AND TECHNOLOGICAL ADVANCEMENTS ARE EXPECTED TO DRIVE THE GLOBAL BACTERIOPHAGES THERAPY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 STAPHYLOCOCCUS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BACTERIOPHAGES THERAPY MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BACTERIOPHAGES THERAPY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR STEM CELL MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL BACTERIOPHAGES THERAPY MARKET
FIGURE 16 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2020
FIGURE 17 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2021-2028 (USD MILLION)
FIGURE 18 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET, CAGR (2021-2028)
FIGURE 19 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET, LIFELINE CURVE
FIGURE 20 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2020
FIGURE 21 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2021-2028 (USD MILLION)
FIGURE 22 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 23 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY BASE, 2020
FIGURE 25 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY BASE, 2021-2028 (USD MILLION)
FIGURE 26 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY BASE, CAGR (2021-2028)
FIGURE 27 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY BASE, LIFELINE CURVE
FIGURE 28 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2020
FIGURE 29 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 30 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 31 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 32 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 33 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
FIGURE 34 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 35 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY END USER, 2020
FIGURE 37 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 38 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY END USER, CAGR (2021-2028)
FIGURE 39 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 41 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 42 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 43 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 GLOBAL BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)
FIGURE 45 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY REGION (2020)
FIGURE 46 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY REGION (2021 & 2028)
FIGURE 47 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY REGION (2020 & 2028)
FIGURE 48 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)
FIGURE 49 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)
FIGURE 50 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)
FIGURE 51 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 52 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 53 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)
FIGURE 54 EUROPE BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)
FIGURE 55 EUROPE BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)
FIGURE 56 EUROPE BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 57 EUROPE BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 58 EUROPE BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)
FIGURE 59 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)
FIGURE 60 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)
FIGURE 61 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 62 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 63 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)
FIGURE 64 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)
FIGURE 65 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)
FIGURE 66 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 67 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 68 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)
FIGURE 69 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)
FIGURE 70 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)
FIGURE 71 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 72 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 73 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)
FIGURE 74 GLOBAL BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
FIGURE 75 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
FIGURE 76 EUROPE BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
FIGURE 77 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.
